Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

By D. McDermott, M. Regan, Joseph I. Clark, L. Flaherty, G. R. Weiss, T. Logan, J. Kirkwood, M. Gordon, J. Sosman, M. Ernstoff and 8 more. Journal of Clinical Oncology, 2005

736 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/109247fe886f78deb970c7ae073d686037117406

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Augusto Ochoa
2. P. Rodriguez

Citations in the corpus

• Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. (2005, methodology): “Samples. Frozen pretreatment PBMC from 123 metastatic RCC patients participating in a Cytokine Working Group trial ( 3 ) and 33 normal controls with similar age and gender distributions were initially studied.”
• Arginase I–Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes (2009, neutral): “However, response is limited to 15% to 23% of patients (1).”